In a patient with cholelithiasis undergoing surgery who is taking semaglutide (Ozempic), how should the semaglutide be managed perioperatively?

Perioperative Management of Semaglutide in Cholelithiasis Surgery

For patients with cholelithiasis undergoing surgery who are taking semaglutide, the medication should be held for at least 3 weeks (approximately 3 half-lives) before elective surgery due to the risk of delayed gastric emptying and aspiration, with consideration for gastric ultrasound assessment if surgery cannot be delayed.

Critical Safety Concern: Aspiration Risk

The primary perioperative concern with semaglutide is delayed gastric emptying, which persists well beyond standard fasting periods and significantly increases aspiration risk under anesthesia. The most recent multidisciplinary consensus 1 emphasizes that semaglutide's half-life of approximately 1 week 2 means gastric effects can persist for weeks after discontinuation.

Evidence-Based Discontinuation Timeline

The 2024 American Diabetes Association guidelines explicitly state: "There are little data on the safe use and/or influence of GLP-1 receptor agonists on glycemia and delayed gastric emptying in the perioperative period" 3. This lack of data has led to conservative recommendations.

The strongest recent evidence 1 recommends:

• For weight loss indication: Hold for at least 3 half-lives (approximately 3 weeks for semaglutide) before surgery
• For diabetes indication: Consult endocrinology regarding risks/benefits of holding for 3 half-lives versus continuing with enhanced aspiration precautions

Research data supports this approach: A 2024 retrospective study 4 found that preoperative semaglutide interruption >21 days in symptomatic patients and >14 days in asymptomatic patients resulted in residual gastric content rates similar to non-users. Another 2026 study 5 demonstrated that 4-week discontinuation normalized complication rates to control levels (10% vs 45% when continued).

Specific Management Algorithm

Step 1: Assess Patient Status (Preoperatively)

• Document: Last semaglutide dose, indication (diabetes vs weight loss), current dose, presence of GI symptoms (nausea, vomiting, bloating)
• Timing: Ideally identify semaglutide use at surgical scheduling, not day of surgery

Step 2: Determine Discontinuation Strategy

For elective cholecystectomy:

• Weight loss indication: Discontinue 3 weeks before surgery (mandatory)
• Diabetes indication: Discontinue 3 weeks before surgery if feasible; if not possible, proceed to Step 3

If patient presents with <3 weeks discontinuation:

• Consider rescheduling elective surgery
• If surgery cannot be delayed, proceed to enhanced aspiration precautions (Step 3)

Step 3: Enhanced Aspiration Risk Mitigation (When Discontinuation <3 Weeks)

The 2024 consensus guidelines 1 recommend:

1. Preoperative gastric ultrasound to assess residual gastric contents 6

   • If empty stomach confirmed: Proceed with standard rapid sequence induction
   • If gastric contents present: Implement full aspiration precautions or reschedule

2. Dietary modification: Clear liquid diet for 24-48 hours before surgery (beyond standard NPO)

3. Consider prokinetic agents: Metoclopramide or erythromycin preoperatively 1

4. Anesthetic technique:

   • Treat as full stomach: Rapid sequence induction with cricoid pressure
   • Consider awake fiberoptic intubation for high-risk patients
   • Avoid deep sedation without airway protection

Step 4: Perioperative Glucose Management

Since semaglutide must be held, implement alternative diabetes management per ADA 2024 guidelines 3:

• Target glucose: 100-180 mg/dL perioperatively
• Monitor glucose every 2-4 hours while NPO
• Insulin coverage: Basal-bolus regimen (give 75-80% of usual long-acting insulin dose or half of NPH dose on day of surgery)
• Avoid correction-only insulin: Use scheduled basal insulin plus short/rapid-acting for meals

Step 5: Postoperative Resumption

• Restart semaglutide once patient tolerating regular diet (typically 24-48 hours post-cholecystectomy)
• Monitor closely for GI symptoms during re-initiation
• Resume at previous dose if well-tolerated preoperatively

Critical Pitfalls to Avoid

1. Do not assume standard NPO is sufficient: Case reports 7 document regurgitation after 20-hour fasting in semaglutide users

2. Do not continue semaglutide until day before surgery: Studies show 4 that discontinuation <8 days still carries 10-fold increased risk of residual gastric contents

3. Do not use CGM alone for intraoperative glucose monitoring 3

4. Do not restart semaglutide if patient develops postoperative ileus or persistent nausea

Special Consideration for Cholelithiasis

While not directly addressed in guidelines, one case report 8 documented acalculous cholecystitis rupture in a semaglutide user, potentially related to biliary stasis effects. This underscores the importance of:

• Not delaying necessary cholecystectomy for symptomatic cholelithiasis
• Maintaining high clinical suspicion for biliary complications postoperatively
• Considering whether chronic semaglutide use may have contributed to gallstone formation

The balance for this specific patient population favors discontinuation 3 weeks preoperatively when feasible, as the surgical indication (cholelithiasis) is definitive treatment and temporary glucose elevation is safer than aspiration risk.